Thermo Fisher Scientific (NYSE:TMO) Upgraded by Piper Sandler to “Hold” Rating

Thermo Fisher Scientific (NYSE:TMO) was upgraded by analysts at Piper Sandler to a “hold” rating in a note issued to investors on Thursday,Zacks.com reports.

Several other research analysts have also weighed in on the stock. Robert W. Baird cut their price objective on shares of Thermo Fisher Scientific from $653.00 to $639.00 and set an “outperform” rating on the stock in a report on Friday, April 24th. Weiss Ratings restated a “hold (c)” rating on shares of Thermo Fisher Scientific in a report on Wednesday, April 8th. Jefferies Financial Group upgraded shares of Thermo Fisher Scientific to a “strong-buy” rating in a report on Friday, April 24th. KeyCorp restated an “overweight” rating on shares of Thermo Fisher Scientific in a report on Tuesday, May 26th. Finally, Wolfe Research started coverage on shares of Thermo Fisher Scientific in a report on Tuesday, June 2nd. They issued an “outperform” rating and a $535.00 price target on the stock. Two analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and five have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $608.95.

Thermo Fisher Scientific Trading Down 1.4%

Shares of TMO stock opened at $475.12 on Thursday. The firm has a market cap of $176.56 billion, a P/E ratio of 26.12, a PEG ratio of 2.13 and a beta of 0.88. Thermo Fisher Scientific has a 1-year low of $385.46 and a 1-year high of $643.99. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.53 and a quick ratio of 1.15. The firm’s 50-day simple moving average is $479.68 and its 200-day simple moving average is $528.09.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Thursday, April 23rd. The medical research company reported $5.44 earnings per share for the quarter, topping the consensus estimate of $5.25 by $0.19. The business had revenue of $11.01 billion for the quarter, compared to analyst estimates of $10.86 billion. Thermo Fisher Scientific had a net margin of 15.15% and a return on equity of 16.86%. The company’s revenue was up 6.2% on a year-over-year basis. During the same period in the prior year, the firm posted $5.15 EPS. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. As a group, equities analysts forecast that Thermo Fisher Scientific will post 24.86 EPS for the current year.

Insider Transactions at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, COO Gianluca Pettiti sold 400 shares of the stock in a transaction that occurred on Monday, April 27th. The shares were sold at an average price of $462.66, for a total value of $185,064.00. Following the completion of the sale, the chief operating officer owned 25,051 shares of the company’s stock, valued at $11,590,095.66. This trade represents a 1.57% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.33% of the stock is owned by company insiders.

Institutional Trading of Thermo Fisher Scientific

Large investors have recently bought and sold shares of the company. Dakota Community Bank & Trust NA grew its position in shares of Thermo Fisher Scientific by 33.1% during the first quarter. Dakota Community Bank & Trust NA now owns 193 shares of the medical research company’s stock worth $95,000 after buying an additional 48 shares in the last quarter. Rathbones Group PLC increased its stake in shares of Thermo Fisher Scientific by 2.9% in the first quarter. Rathbones Group PLC now owns 953,908 shares of the medical research company’s stock worth $468,874,000 after buying an additional 27,175 shares during the last quarter. Pine Valley Investments Ltd Liability Co increased its stake in shares of Thermo Fisher Scientific by 1.1% in the first quarter. Pine Valley Investments Ltd Liability Co now owns 17,379 shares of the medical research company’s stock worth $8,543,000 after buying an additional 185 shares during the last quarter. DV Trading LLC increased its stake in shares of Thermo Fisher Scientific by 193.8% in the first quarter. DV Trading LLC now owns 470 shares of the medical research company’s stock worth $231,000 after buying an additional 310 shares during the last quarter. Finally, Parallel Advisors LLC increased its stake in shares of Thermo Fisher Scientific by 3.2% in the first quarter. Parallel Advisors LLC now owns 37,051 shares of the medical research company’s stock worth $18,212,000 after buying an additional 1,157 shares during the last quarter. Institutional investors and hedge funds own 89.23% of the company’s stock.

About Thermo Fisher Scientific

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.